OncoSil™
to treat patients with locally advanced unresectable pancreatic cancer (LAPC)
OncoSil™, is a single-use brachytherapy (internal radiation) device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. It is used in combination with chemotherapy.
OncoSil™ contains radioactive Phosphorus (P-32) microparticles as its active ingredient. These microparticles range in diameter from 28 to 32 micrometers, which is smaller than the width of a human hair. Once the OncoSil™ microparticles are placed, they remain permanently in the tumor.
- OncoSil™ is injected directly into the pancreatic tumor under endoscopic ultrasound guidance.
- The purpose of OncoSil™ is to deliver radiation directly to the tumor with Phosphorus-32 (P-32) to destroy cancer cells.
- After the device is placed, 98% of the radiation is delivered within 81 days, and the OncoSil™ microparticles remain permanently in the tumor. The microparticles have been tested to ensure long-term safety.
- The beta radiation emitted by OncoSil™ travels a short distance to reach the tumor tissue, causing direct damage to the DNA of cancer cells.
- This damage prevents cancer cells from further dividing and proliferating.
- By stopping cell division and proliferation, OncoSil™ can prevent the growth of cancer cells, ultimately reducing the tumor mass as the cancer cells eventually die.
Publications
- Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/ nab-paclitaxel or FOLFIRINOX chemotherapy
We're ready to collaborate!
You can contact us to learn more about our products and solutions and to get acquainted.
